Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

Core Insights - Corcept Therapeutics has seen its shares increase by approximately 11.7% since the last earnings report, outperforming the S&P 500 [1] Financial Performance - In Q4 2025, Corcept reported earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.27, and down from $0.26 per share in the same quarter last year [2] - Revenues for Q4 2025 rose by around 11.1% year over year to $202.1 million, but fell short of the Zacks Consensus Estimate of $254 million, primarily driven by sales of the Cushing's syndrome drug, Korlym [3] - Korlym revenue missed the model estimate of $250 million [4] - Research and development expenses decreased by 7.7% year over year to $64.9 million, while selling, general, and administrative expenses increased by approximately 56.1% year over year to $130.2 million, leading to a total operating expense increase of 26.2% year over year to $197.6 million [4] - As of December 31, 2025, cash and investments totaled $532.4 million, up from $524.2 million as of September 30, 2025 [4] Future Guidance - Corcept anticipates total revenues in the range of $900 million to $1 billion for 2026 [5] Estimate Trends - Recent estimates for Corcept have trended downward, with a consensus estimate shift of -12.66% over the past month [6] - The stock currently holds a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [8] Industry Comparison - Corcept operates within the Zacks Medical - Drugs industry, where competitor Madrigal (MDGL) has reported a revenue increase of 210.8% year over year, totaling $321.08 million in its last quarter [9] - Madrigal's EPS for the same period was -$2.57, an improvement from -$2.71 a year ago, and it has a Zacks Rank of 3 (Hold) [10]